News & Events

3 Jul, 2024

Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication

READ MORE...

23 May, 2024

Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference

READ MORE...

2 May, 2024

Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024

READ MORE...

2 Oct, 2023

Pneumagen Announces Successful Clinical Proof of Concept for its Broad-Spectrum Antiviral Neumifil in Phase 2 Influenza Human Challenge Study

READ MORE...

1 Jun, 2023

Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infections

READ MORE...

18 Apr, 2023

Pneumagen further strengthens IP protection for lead product Neumifil with granting of US composition of matter patent

READ MORE...

6 Jan, 2023

Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors

READ MORE...

28 Sep, 2022

Pneumagen Creates International Clinical Advisory Group of World Leading Respiratory and Infectious Disease Experts

READ MORE...

16 Aug, 2022

Pneumagen Announces First Patient Dosed in Phase 2 Proof of Concept Influenza Challenge Study Assessing Neumifil, an Intranasal Broad-Spectrum Antiviral

READ MORE...